Youssef, Gannam and Mostapha, Abdi El and Achraf, Chadli and Youssef, Bencherki and Amine, Moataz and Mohamed, Dakir and Adil, Debbagh and Rachid, Aboutaieb (2022) Rare Case of Renal Tumor: Carcinoma with Xp11 Translocation. Asian Journal of Research in Surgery, 5 (1). pp. 31-34.
Mostapha512022AJRS87123.pdf - Published Version
Download (289kB)
Abstract
Adult renal cell carcinomas are divided into four types: clear cell carcinomas, papillary carcinomas and chromophobe carcinomas. Cytogenetic analysis has led to the discovery of a new variant of renal cell carcinoma, the "Xp11.2 translocation related carcinoma".
The aim of this article is to report a rare case of renal cell carcinoma in our current practice with a review of the literature.
The patient is 21 years old, with no particular pathological history. The history of the disease goes back to 5 years with the appearance of intermittent coagulant total hematuria without any other associated sign.
Urogenital examination revealed lumbar tenderness with a positive left lumbar contact.
A biological workup was requested showing an anemia of 6.5 g/dl, grouping: B+.
A normal renal function with a creatinemia of 11 mg /l.
A radiological workup (Uroscanner) was also requested, showing a large left renal tumor process occupying almost the entire kidney, estimated at 19.5*14*12.5 cm in the major axes.
The patient underwent a transfusion of packed red blood cells and then an enlarged total nephrectomy with a pre aortic-cavity lymph node curage.
Genetic examination is the reference diagnosis. It is requested in first intention to allow a decision to be made after an equivocal immunohistochemical examination.
The evolution of renal tumor with Xp11.2 translocation is often negative in adults, with a high risk of lymph node metastasis. The evolution of our patient was marked by a good clinical and biological improvement with absence of low back pain, hematuria and normalization of the hemoglobin level. In conclusion, the carcinoma with translocation Xp11.2 is a rare form of renal tumor and the management is multidisciplinary involving the urology surgeon, the anatomopathologist and the oncologist. The therapeutic management must be early to improve the vital prognosis.
Item Type: | Article |
---|---|
Subjects: | Euro Archives > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 28 Feb 2023 08:11 |
Last Modified: | 15 Apr 2024 10:24 |
URI: | http://publish7promo.com/id/eprint/1723 |